Titre : Mitomycine

Mitomycine : Questions médicales fréquentes

{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Mitomycine : Questions médicales les plus fréquentes", "headline": "Mitomycine : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Mitomycine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-23", "dateModified": "2025-02-17", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Mitomycine" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Mitomycines", "url": "https://questionsmedicales.fr/mesh/D008937", "about": { "@type": "MedicalCondition", "name": "Mitomycines", "code": { "@type": "MedicalCode", "code": "D008937", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.473.412.249" } } }, "about": { "@type": "MedicalCondition", "name": "Mitomycine", "alternateName": "Mitomycin", "code": { "@type": "MedicalCode", "code": "D016685", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Elise Champeil", "url": "https://questionsmedicales.fr/author/Elise%20Champeil", "affiliation": { "@type": "Organization", "name": "John Jay College of Criminal Justice, New York, 524 West 59(th) Street, New York, NY 10019, USA; The Graduate Center of the City University of New York, New York, NY 10016, USA. Electronic address: echampeil@jjay.cuny.edu." } }, { "@type": "Person", "name": "Owen Zacarias", "url": "https://questionsmedicales.fr/author/Owen%20Zacarias", "affiliation": { "@type": "Organization", "name": "Department of Sciences, John Jay College of Criminal Justice, New York, NY 10019, United States." } }, { "@type": "Person", "name": "Maggie Zheng", "url": "https://questionsmedicales.fr/author/Maggie%20Zheng", "affiliation": { "@type": "Organization", "name": "John Jay College of Criminal Justice, New York, 524 West 59(th) Street, New York, NY 10019, USA. Electronic address: maggie.zheng@jjay.cuny.edu." } }, { "@type": "Person", "name": "Timothy Snyder", "url": "https://questionsmedicales.fr/author/Timothy%20Snyder", "affiliation": { "@type": "Organization", "name": "John Jay College of Criminal Justice, New York, 524 West 59(th) Street, New York, NY 10019, USA. Electronic address: timothy.snyder@jjay.cuny.edu." } }, { "@type": "Person", "name": "Gloria Proni", "url": "https://questionsmedicales.fr/author/Gloria%20Proni", "affiliation": { "@type": "Organization", "name": "John Jay College of Criminal Justice, New York, 524 West 59(th) Street, New York, NY 10019, USA. Electronic address: gproni@jjay.cuny.edu." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Efficacy and Safety of the Preserflo Microshunt With Mitomycin C for the Treatment of Open Angle Glaucoma.", "datePublished": "2022-05-17", "url": "https://questionsmedicales.fr/article/35583510", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/IJG.0000000000002052" } }, { "@type": "ScholarlyArticle", "name": "RecA and RecB: probing complexes of DNA repair proteins with mitomycin C in live", "datePublished": "2022-08-10", "url": "https://questionsmedicales.fr/article/35946163", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1098/rsif.2022.0437" } }, { "@type": "ScholarlyArticle", "name": "Effects of cyclophosphamide and mitomycin C on radiation-induced transcriptional biomarkers in human lymphoblastoid cells.", "datePublished": "2023-08-07", "url": "https://questionsmedicales.fr/article/37530590", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/09553002.2023.2241907" } }, { "@type": "ScholarlyArticle", "name": "Insight Into Factors Governing Formation, Synthesis and Stereochemical Configuration of DNA Adducts Formed by Mitomycins.", "datePublished": "2022-10-17", "url": "https://questionsmedicales.fr/article/36251922", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/tcr.202200193" } }, { "@type": "ScholarlyArticle", "name": "Effect of ripasudil after trabeculectomy with mitomycin C: a multicentre, randomised, prospective clinical study.", "datePublished": "2024-07-02", "url": "https://questionsmedicales.fr/article/38960415", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/bmjophth-2023-001449" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétérocycliques à cycles fusionnés", "item": "https://questionsmedicales.fr/mesh/D000072471" }, { "@type": "ListItem", "position": 4, "name": "Composés hétérobicycliques", "item": "https://questionsmedicales.fr/mesh/D006574" }, { "@type": "ListItem", "position": 5, "name": "Indoles", "item": "https://questionsmedicales.fr/mesh/D007211" }, { "@type": "ListItem", "position": 6, "name": "Indolequinones", "item": "https://questionsmedicales.fr/mesh/D045563" }, { "@type": "ListItem", "position": 7, "name": "Mitomycines", "item": "https://questionsmedicales.fr/mesh/D008937" }, { "@type": "ListItem", "position": 8, "name": "Mitomycine", "item": "https://questionsmedicales.fr/mesh/D016685" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Mitomycine - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Mitomycine", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-01", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Mitomycine", "description": "Comment la mitomycine est-elle administrée ?\nQuels tests sont nécessaires avant traitement ?\nLa mitomycine est-elle utilisée pour tous les cancers ?\nQuels marqueurs tumoraux sont surveillés ?\nY a-t-il des contre-indications au traitement ?", "url": "https://questionsmedicales.fr/mesh/D016685?page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Mitomycine", "description": "Quels sont les effets secondaires courants ?\nLa mitomycine cause-t-elle des douleurs ?\nQuels symptômes indiquent une réaction allergique ?\nPeut-elle affecter le système immunitaire ?\nQuels signes de toxicité doivent alerter ?", "url": "https://questionsmedicales.fr/mesh/D016685?page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Mitomycine", "description": "Comment minimiser les effets secondaires ?\nDes vaccinations sont-elles nécessaires ?\nComment éviter les infections pendant le traitement ?\nY a-t-il des recommandations alimentaires ?\nComment gérer le stress pendant le traitement ?", "url": "https://questionsmedicales.fr/mesh/D016685?page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Mitomycine", "description": "La mitomycine est-elle utilisée seule ?\nQuelle est la durée du traitement ?\nComment surveiller l'efficacité du traitement ?\nQuels soins de soutien sont recommandés ?\nY a-t-il des interactions médicamenteuses ?", "url": "https://questionsmedicales.fr/mesh/D016685?page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Mitomycine", "description": "Quelles sont les complications possibles ?\nLa mitomycine peut-elle causer des cancers secondaires ?\nComment gérer une toxicité sévère ?\nQuels tests pour surveiller les complications ?\nY a-t-il des effets à long terme ?", "url": "https://questionsmedicales.fr/mesh/D016685?page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Mitomycine", "description": "Qui est à risque d'effets secondaires ?\nLes antécédents de cancer augmentent-ils le risque ?\nLe tabagisme influence-t-il le traitement ?\nY a-t-il des facteurs génétiques à considérer ?\nL'âge influence-t-il la tolérance au traitement ?", "url": "https://questionsmedicales.fr/mesh/D016685?page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment la mitomycine est-elle administrée ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "La mitomycine est généralement administrée par injection intraveineuse ou intravésicale." } }, { "@type": "Question", "name": "Quels tests sont nécessaires avant traitement ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des examens d'imagerie sont souvent requis pour évaluer la santé du patient." } }, { "@type": "Question", "name": "La mitomycine est-elle utilisée pour tous les cancers ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Non, elle est principalement utilisée pour des cancers spécifiques comme le cancer de la vessie." } }, { "@type": "Question", "name": "Quels marqueurs tumoraux sont surveillés ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les marqueurs comme le CA 19-9 peuvent être surveillés selon le type de cancer traité." } }, { "@type": "Question", "name": "Y a-t-il des contre-indications au traitement ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents d'allergies ou de maladies rénales peuvent être des contre-indications." } }, { "@type": "Question", "name": "Quels sont les effets secondaires courants ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent nausées, vomissements, et fatigue." } }, { "@type": "Question", "name": "La mitomycine cause-t-elle des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut provoquer des douleurs abdominales ou des douleurs au site d'injection." } }, { "@type": "Question", "name": "Quels symptômes indiquent une réaction allergique ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des démangeaisons, éruptions cutanées ou difficultés respiratoires peuvent indiquer une allergie." } }, { "@type": "Question", "name": "Peut-elle affecter le système immunitaire ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la mitomycine peut réduire les globules blancs, augmentant le risque d'infections." } }, { "@type": "Question", "name": "Quels signes de toxicité doivent alerter ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des saignements inhabituels ou des ecchymoses peuvent indiquer une toxicité." } }, { "@type": "Question", "name": "Comment minimiser les effets secondaires ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une bonne hydratation et des médicaments antiémétiques peuvent aider à réduire les effets secondaires." } }, { "@type": "Question", "name": "Des vaccinations sont-elles nécessaires ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Des vaccinations peuvent être recommandées pour prévenir les infections pendant le traitement." } }, { "@type": "Question", "name": "Comment éviter les infections pendant le traitement ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les foules et pratiquer une bonne hygiène peut aider à prévenir les infections." } }, { "@type": "Question", "name": "Y a-t-il des recommandations alimentaires ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et riche en nutriments est recommandée pour soutenir le traitement." } }, { "@type": "Question", "name": "Comment gérer le stress pendant le traitement ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Des techniques de relaxation et le soutien psychologique peuvent aider à gérer le stress." } }, { "@type": "Question", "name": "La mitomycine est-elle utilisée seule ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut être utilisée seule ou en combinaison avec d'autres agents chimiothérapeutiques." } }, { "@type": "Question", "name": "Quelle est la durée du traitement ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La durée varie selon le type de cancer, mais elle est souvent administrée sur plusieurs cycles." } }, { "@type": "Question", "name": "Comment surveiller l'efficacité du traitement ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des examens d'imagerie et des tests sanguins réguliers sont utilisés pour évaluer l'efficacité." } }, { "@type": "Question", "name": "Quels soins de soutien sont recommandés ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des soins de soutien comme la gestion de la douleur et des conseils nutritionnels sont recommandés." } }, { "@type": "Question", "name": "Y a-t-il des interactions médicamenteuses ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la mitomycine peut interagir avec d'autres médicaments, nécessitant une surveillance." } }, { "@type": "Question", "name": "Quelles sont les complications possibles ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent inclure des infections, des saignements et des problèmes rénaux." } }, { "@type": "Question", "name": "La mitomycine peut-elle causer des cancers secondaires ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'utilisation de mitomycine peut augmenter le risque de cancers secondaires à long terme." } }, { "@type": "Question", "name": "Comment gérer une toxicité sévère ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Une hospitalisation et un traitement symptomatique peuvent être nécessaires en cas de toxicité sévère." } }, { "@type": "Question", "name": "Quels tests pour surveiller les complications ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins réguliers et des examens d'imagerie sont nécessaires pour surveiller les complications." } }, { "@type": "Question", "name": "Y a-t-il des effets à long terme ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des effets à long terme peuvent inclure des problèmes pulmonaires ou rénaux, nécessitant un suivi." } }, { "@type": "Question", "name": "Qui est à risque d'effets secondaires ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes âgées et celles avec des antécédents médicaux complexes sont plus à risque." } }, { "@type": "Question", "name": "Les antécédents de cancer augmentent-ils le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de cancer peuvent augmenter le risque d'effets secondaires lors du traitement." } }, { "@type": "Question", "name": "Le tabagisme influence-t-il le traitement ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut affecter l'efficacité du traitement et augmenter les risques d'effets secondaires." } }, { "@type": "Question", "name": "Y a-t-il des facteurs génétiques à considérer ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Certaines variations génétiques peuvent influencer la réponse au traitement par mitomycine." } }, { "@type": "Question", "name": "L'âge influence-t-il la tolérance au traitement ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients plus âgés peuvent avoir une tolérance réduite aux effets de la mitomycine." } } ] } ] }

Sources (257 au total)

Efficacy and Safety of the Preserflo Microshunt With Mitomycin C for the Treatment of Open Angle Glaucoma.

The Preserflo Microshunt (PSM) is a safe and effective glaucoma microfiltering implant that significantly reduces the intraocular pressure (IOP), either alone or in combination with phacoemulsificatio... The purpose of this study was to assess the safety and efficacy of the PSM for the treatment of open angle glaucoma with 0.2 mg/mL mitomycin C, either alone or in combination with cataract surgery.... A retrospective, open-label study of 64 eyes with primary open angle glaucoma that underwent PSM implantation and were followed up for at least 9 months. Success was defined as IOP 6-17 mm Hg and a re... A total of 51 eyes underwent PSM alone and 13 underwent PSM+phacoemulsification. In the overall population of the study, the mean IOP was significantly reduced from 22.03±0.7 mm Hg at baseline to 12.7... Glaucoma surgery with the PSM and mitomycin C was efficacious and safe in the short term, either alone or in combination with cataract surgery, and may be considered a surgical option for lowering IOP...

Effects of cyclophosphamide and mitomycin C on radiation-induced transcriptional biomarkers in human lymphoblastoid cells.

Ionizing radiation (IR)-induced transcriptional changes are considered a potential biodosimetry for dose evaluation and health risk monitoring of acute or chronic radiation exposure. It is crucial to ... The human B lymphoblastoid cells (AHH-1) were exposed to 0, 20, 50, 100, 200 and 500 μg/ml CP or 0, 0.025, 0.05, 0.1 and 1 μg/ml MMC, respectively. The appropriate concentrations of CP and MMC were ad... The baseline transcriptional levels of the 18 selected genes were slightly affected by CP treatment in the absence of IR, while the transcript responses to IR could be inhibited as the concentration o... Our findings suggested that IR-induced gene expression changes were slightly affected after exposure to a relatively low concentration of CP and MMC. Gene expression combinations might improve the bro...

Effect of ripasudil after trabeculectomy with mitomycin C: a multicentre, randomised, prospective clinical study.

To investigate if there are improvements in trabeculectomy outcomes supporting filtration bleb formation caused by Rho-associated protein kinase (ROCK) inhibitors.... This prospective, multicentre, randomised, open-label clinical study examined open-angle glaucoma patients who underwent trabeculectomy or trabeculectomy combined with cataract surgery followed by 3-m... A total of 17 and 15 subjects dropped out in the ripasudil group and non-ripasudil group, respectively. At baseline, the mean IOP was 16.8±5.0 mm Hg in the ripasudil group (38 patients) and 16.2±4.4 i... Although ripasudil application did not increase the primary trabeculectomy success rate, it did reduce IOP-lowering medications after trabeculectomy with mitomycin C....

Outcomes of the Aurolab aqueous drainage implant and trabeculectomy with mitomycin C in iridocorneal endothelial syndrome.

To compare the surgical outcomes of the Aurolab aqueous drainage implant (AADI) and trabeculectomy with mitomycin C (MMC) in patients with glaucoma secondary to iridocorneal endothelial (ICE) syndrome... This retrospective comparative case series included 41 eyes of 41 patients with ICE syndrome and glaucoma who underwent either a trabeculectomy with MMC (n = 20) or AADI surgery (n = 21) with a minimu... The cumulative probability of failure at 2 years was 50% in the trabeculectomy group (95%CI = 31-83%) and 24% in the AADI group (95%CI = 11-48%) (p = 0.09). The IOP was consistently lower in the AADI ... AADI surgery achieved lower mean IOPs than trabeculectomy with MMC in managing glaucoma secondary to ICE syndrome. A trend toward lower rates of surgical failure and reoperations for glaucoma and comp...

Efficacy and safety of intraoperative injection of mitomycin C during trabeculectomy: a systematic review and meta-analysis.

Trabeculectomy, a primary surgical treatment for glaucoma, often employs mitomycin C (MMC) to reduce scar formation and improve surgical outcomes. However, the optimal application method of MMC, wheth... A comprehensive literature search of Scopus, MEDLINE, EMBASE, Ovid, Chinese biomedical literature database, China National Knowledge Infrastructure, and Cochrane Library was done for eligible studies ... A total of 15 studies with 1276 participants were included. The meta-analysis revealed no significant difference in IOP reduction between patients treated by MMC injection and sponge application (WMD ... This meta-analysis indicated that while both injection and sponge methods of MMC application during trabeculectomy were equally effective for IOP reduction, they differ in their impact on bleb morphol...

The effect of uneventful cataract surgery in pseudoexfoliation glaucoma with or without previous mitomycin C-augmented trabeculectomy.

To analyze the effect of uneventful cataract surgery on intraocular pressure (IOP) in pseudoexfoliation glaucoma (PXG) eyes with and without a history of Mitomycin C-augmented trabeculectomy.... Eyes with PXG that had underwent uneventful cataract surgery were enrolled. The IOP and the medication numbers before cataract surgery, and 1, 3, 6, 12, 18, 24 months after cataract surgery, and at th... In the trabeculectomized eyes (n = 37), the increase in the mean IOP (p = 0.024) and the increase in the mean number of medications (p = 0.007) was significant at the last visit when compared with bas... Uneventful cataract surgery may have significant negative effect on the IOP control in the trabeculectomized PXG eyes. After cataract surgery, the non-trabeculectomized PXG eyes had a higher risk of I...